α-Glucosidase-IN-105
α-Glucosidase-IN-105 is a selective and potent α-Glucosidase inhibitor with an IC50 of 31.36 μM. α-Glucosidase-IN-105 also inhibits α-Amylase (IC50 = 104.2 μM). α-Glucosidase-IN-105 exhibits inhibitory effects comparable to the standard drug Acarbose. α-Glucosidase-IN-105 can be used for the research of type 2 diabetes[1].
Product Specifications
UNSPSC
12352005
Target
Amylases; Glycosidase
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Metabolic Disease
Smiles
COC(C=C1)=CC=C1C2=NN(C3=CC=CC=C3)C=C2/C4=C5C=CC(/C(C6=CN(C7=CC=CC=C7)N=C6C8=CC=C(OC)C=C8)=C9C=C/C(N/9)=C(C(C=C/%10)=NC%10=C(C%11=CC=C4N%11)\C%12=CN(N=C%12C%13=CC=C(OC)C=C%13)C%14=CC=CC=C%14)\C%15=CN(N=C%15C%16=CC=C(OC)C=C%16)C%17=CC=CC=C%17)=N\5
Molecular Formula
C84H62N12O4
Molecular Weight
1303.47
References & Citations
[1]Peddakotla SVK, et al. Design, synthesis, α-glucosidase inhibitory activity, and molecular docking of novel pyrazolyl-porphyrin hybrids as potential antidiabetic agents. Bioorg Med Chem Lett. 2026;131:130462.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Glucosidase
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15120687 1 Vial
Lentiviral human BORA shRNA (UAS) - Lentiviral human BORA shRNA (UAS, iRFP) (100)
Sign In for Pricing
View Details